What is eSym?

If you are a Baptist Cancer Center patient, a new app called eSyM could make your life a little easier. eSyM gives you a direct line to your doctor, making it easier to get quick answers to your treatment questions. We are testing the app as part of a national study, and we would love your input.

To participate, you must be undergoing chemotherapy at Baptist Cancer Center. If you’re interested in participating, please fill out the following form.

Fill out my online form.

In the fall of 2018, Baptist Cancer Center joined the SIMPRO Research Center. Its purpose is to determine if the eSyM app improves symptom management and decreases hospitalizations among cancer patients.

The app is being developed by and will be deployed through Epic.

To participate, you must have a MyChart account through Baptist OneCare (Baptist’s electronic health record powered by Epic.) If you do not have an account, someone will contact you to set one up.

How does eSyM benefit you as a patient?

  • Quick access to your physician and care team without having to place a phone call
  • Prompt answers to your questions and concerns
  • Greater peace of mind in having your symptoms/questions addressed quickly
  • Guidance on whether you need to seek immediate care

How do I sign up? Am I eligible?

To qualify, you must be must be a patient at Baptist Cancer Center and be undergoing chemotherapy. Please fill out the below form, and someone will contact you to enroll you.

About the SIMPRO Research Center

In the fall of 2018, Baptist Cancer Center was named as one of six health care systems in the U.S. to be part of a research collaboration funded by The National Cancer Institute in association with the Beau Biden Cancer Moonshot Initiative. The collaboration is known as the SIMPRO Research Center. Its purpose is to use the eSyM app as a way to improve symptom management and decrease hospitalizations among oncology patients.

Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.